Literature DB >> 421545

Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases.

D Y Rosenzweig.   

Abstract

One hundred consecutive cases of pulmonary infection due to Mycobacterium intracellulare-avium seen during a 3 1/2-year period qualified for review on the basis of a compatible chest x-ray film, repeated isolations from cultures of sputum, and follow-up of three to eight years. Infections with M intracellulare-avium represented 27 percent of all mycobacterial infections seen during this period, including those due to M tuberculosis. The cases of disease due to M intracellulare-avium were predominantly in men with preexisting pulmonary disease, with a peak incidence in the sixth decade, but nearly one-third of the cases were in younger persons free of coexisting disease. The disease was chronic and indolent in most cases, and only a few showed a progressive course. A stable course was frequently observed despite prolonged persistently positive cultures of sputum. A favorable prognosis was most often found in those with previously treated tuberculosis. Poor prognosis was often due to a serious associated disease, such as cancer, rather than to advancing mycobacterial infection itself. Age, sex, or race was unrelated to prognosis. Conversion to negative status on culture was attained in one-half of the cases. Those with extensive radiographic involvement or cavitation were more likely to have treatment fail bacteriologically. No combination of chemotherapy appeared to be particularly effective, including the use of five or more drugs in eight cases demonstrating progressive disease. Surgery, too, was ultimately disappointing in that recurrence appeared in six of 18 carefully selected cases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 421545     DOI: 10.1378/chest.75.2.115

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  43 in total

Review 1.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

2.  Mycobacterium avium genes associated with the ability to form a biofilm.

Authors:  Yoshitaka Yamazaki; Lia Danelishvili; Martin Wu; Molly Macnab; Luiz E Bermudez
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

3.  Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation.

Authors:  Emily Henkle; Shannon A Novosad; Sean Shafer; Katrina Hedberg; Sarah A R Siegel; Jennifer Ku; Cara Varley; D Rebecca Prevots; Theodore K Marras; Kevin L Winthrop
Journal:  Ann Am Thorac Soc       Date:  2017-07

Review 4.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

5.  Binding of Mycobacterium avium-Mycobacterium intracellulare to human leukocytes.

Authors:  A Catanzaro; S D Wright
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

6.  ATP synthase inhibition of Mycobacterium avium is not bactericidal.

Authors:  Nacer Lounis; Tom Gevers; Joke Van den Berg; Luc Vranckx; Koen Andries
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 7.  Risk-benefit assessment of therapies for Mycobacterium avium complex infections.

Authors:  D E Griffith
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 8.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

9.  Mycobacterium avium-intracellulare contamination of mammalian cell cultures.

Authors:  I H Lelong-Rebel; Y Piemont; M Fabre; G Rebel
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-10-15       Impact factor: 2.416

10.  Evaluation of abdominal pain in the AIDS patient.

Authors:  D A Potter; D N Danforth; A M Macher; D L Longo; L Stewart; H Masur
Journal:  Ann Surg       Date:  1984-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.